Genmab — November 2018
-
Simon Hagbart Madsen i kommentaren.
Han understreger dog, at den langsigtede investeringscase er intakt.- Daratumumab udviser stort potentiale i behandlingen af knoglemarvskræft, og udbredelsen af behandlingen vil fortsætte i de kommende år, konstaterer han videre og forklarer:
- På trods af et fortsat attraktivt langsigtet potentiale, stiller vi os på sidelinjen som følge af risikoen for et negativt kortsigtet nyhedsflow.
-
ORAL ORDER: Having reviewed the parties' request to schedule a telephone conference (D.I. 439) regarding Plaintiff's motion to strike (D.I. 419), IT IS HEREBY ORDERED that (1) the Court will hear argument on the pending motions to strike (D.I. 419, 435) at the oral argument to be held on November 27, 2018 at 9 a.m.; and (2) each side will have a total of one hour to argue all pending motions. Ordered by Judge Leonard P. Stark on 11/21/2018. (etg)
-
Børsen analyse 9.39. https://borsen.dk/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
